Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

BACKGROUND: Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets. Objective: To evaluate the activity and safety of apalutamide in patients with high-risk nonmetast...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol
Main Authors: Smith, Matthew R., Antonarakis, Emmanuel S., Ryan, Charles J., Berry, William R., Shore, Neal D., Liu, Glenn, Alumkal, Joshi J., Higano, Celestia S., Maneval, Edna Chow, Bandekar, Rajesh, de Boer, Carla J., Yu, Margaret K., Rathkopf, Dana E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5568792/
https://ncbi.nlm.nih.gov/pubmed/27160947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.04.023
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados